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SYNOPSIS
1
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"SYNTHESIS, SPECTRAL STUDIES AND THERAPEUTIC
ACTIVITY OF HETEROCYCLIC COMPOUNDS
The work presented in the thesis with the title "SYNTHESIS,
SPECTRAL STUDIES AND THERAPEUTIC ACTIVITY OF
HETEROCYCLIC COMPOUNDS" included substituted Dibenz [b,f]
azepines derivatives.
The aim  research is to be devlop new bioactive entitles, especially with
antimicrobial activities bearing  heterocyclic ring system namely dibenz [b,f]
azepine.
Dibenz [b,f] azepine represent one of the most class of compounds
possessing a wide spectrum of bactericidal, fungicidal, antitumar, anti
inflammetry, antihypertensive activities etc. Keeping in association with dibenz
[b,f] azepines of various activities, it was worthwhile to synthesise some new
dibenz [b,f] azepines derivatives, which have been described as under.
PART - I STUDIES ON CHALCONES
Chalcones are phenyl strylketones contaning reactive  keto ethylenic
group (-C-CH=CH-) literature reveals that chalcone derivaties possess
antibacterial, antiviral, antispasmodic activities. Hence it was thought worth
while synthesis chalcone derivaties, which have been described are as under.
SECTION - I :  Synthesis and antimicrobial activity of 5-{4'-[(3''-aryl)
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The chalcone derivatives of Type -(I) have been synthesised by the
condensation of 5-[(4'-acetyl Phenyl) carbamido] dibenz [b,f]  azepine with
aromatic aldehyde in presence of 40% NaOH solution
PART - II  STUDIES ON  ISOXAZOLES
Isoxazole derivatives are the potent biological activities. These have
been reported to be active as antibacterial, antifungal, insecticidal and
antiallergic. In order to achieving better potency different isoxazole
derivatives have been described as under.
SECTION - I Synthesis and antimicrobial activity of 5-{4'-[(5"-
aryl)-isoxazole-3''-yl] Phenyl carbamido} - dibenz
[b,f] azepines.
Isoxazoles of Type -(II) have been synthesised by chemoselective
cyclisation between chalcones of Type (I) with hydroxy amine hydro
chloride.
PART - III STUDIES  ON  PYRAZOLINES
Pyrazoline  derivatives possess broad spectrum of
pharmacological activities which are reflected by their use as analgesic,
antiinflammatory, anticonvulsant, insecticidal, herbicidal, antimicrobial
and antipyretic agents. With a view of above facts some new pyrazolines
have been synthesis which have been described as under.
SECTION - I Synthesis and antimicrobial activity of 5-{4'-[(5"-
aryl)- 4"-5"- dihydro - 1"-(H)- pyrazol-3"-yl]
phenyl carbamido} - dibenz [b,f] azepines.
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Type (III)                            R=Aryl
Type (V)                            R=Aryl


















Pyrazoline derivatives of Type : (III) have been synthesised by the
condensation of chalcones of Type (I) with hydrazine hydrate.
SECTION - II : Synthesis and antimicrobial activity of of 5-
{4'-[(5"-aryl)- 4"-5"- dihydro-1"- acetyl
pyrazole-3"-yl] phenyl carbamido}-dibenz
[b,f]- azepines.
Acetyl pyrazoline derivatives of Type : (IV) have been  synthesised
by the condensation of chalcones of Type (I) with acetyl hydrazide.
SECTION- III Synthesis and antimicrobial activity of 5-{4'-
[(5"-aryl)-4"-5"- dihydro-1"-Phenyl pyrazole-
3"- yl]-phenyl carbamido}-dibenz [b,f]
azepines.
4
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Phenyl pyrazoline derivatives of Type (V) have been synthesised by the
condensation of chalcones of Type (I) with phenylhydrazine.
PART - IV STUDIES  ON  PYRIMIDINE  DERIVATIVES
Pyrimidine derivatives are biologically important products and their
synthesis and chemistry have received remarkable attention.  It has been
reported that pyrimidine derivatives are associated with various
biological activities like antifungal, antituberculer, antibacterial, herbicidal
etc. This valid observation led us to synthesis some new medicinally active
compounds synthesised, which have been described as under.
SECTION : I Synthesis and antimicrobial activity of 5-{4'-[(6"-
aryl)-2"- mercapto-3",4"- dihydro pyrimidine - 4"-
yl] -phenyl carbamido} - dibenz [b,f] azepines.
Pyrimidine derivatives of Type : (VI) have been synthesised by the
reaction of the chalcones of Type (I) with thiourea in presence of
alcoholic potassium hydroxide.
SECTION : II Synthesis and antimicrobial activity of 5-{4'-
[(6"-aryl)-2"- hydroxy-3",4"- dihydro
pyrimidine - 4"- yl]- phenyl carbamido} -
dibenz [b,f] azepines.
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Pyrimidine derivatives of Type : (VII) have been synthesised by the
reaction of the chalcones of Type (I) with urea.
SECTION : III Synthesis and antimicrobial activity of 5-{4'-
[(6''- aryl)- 2''- amino -3'',4''- dihydro
pyrimidine - 4''- yl]-phenyl carbamido} -
dibenz [b,f] azepines.
Pyrimidine derivatives of Type : (VIII) have been synthesized by the
reaction of the chalcones of Type-(I) with guanidine hydrochloride.
PART - V STUDIES ON CYANO  PYRIDINES
In recent years, much interest have been focused on the
synthesis of pyridines as the pyridine ring system is associated with
valuable pharmacological activity like antibacterial, antimalarial,
antihypertensive, antifungal, anticonvalsant etc. considering these facts
we thought it is worth while to synthesise some new pyridine derivatives
in association with dibenz [b,f] azepine nucleus in search of better poten-
tial drugs.
SECTION - I Synthesis and antimicrobial activity of 5-{4'-[(6''-
aryl)- 2''- amino -3''- cyano pyridine 4''-yl] phenyl
carbamido} dibenz [b,f] azepines.
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Pyridine derivatives of Type : (IX) have been synthesised by the
reaction of the chalcones of Type (I) with malononitrile  in presence of
ammonium acetate.
SECTION : II Synthesis and antimicrobial activity of 5-{4'-
[(4''- aryl)- 3''-cyano-2''-methoxy pyridine-6''-
yl] phenyl carbamido} - dibenz [b,f] azepines.
Pyridine derivatives of Type : (X) have been synthesised by the
reaction of the chalcone of Type (I) with malononitrile  in presence of
sodium methoxide.
SECTION : III Synthesis and antimicrobial activity of 5-{4'-
[(4''- aryl)- 3''- cyano-2''-ethoxy pyridine-6''-yl-]
-phenyl carbamido} - dibenz [b,f] azepines.
Type (IX)                            R=Aryl





















CH3Type (XI)                            R=Aryl
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Pyridine derivatives of Type : (XI) have been synthesised by the
reaction of  chalcones of Type (I) with malononitrile  in presence of
sodium ethoxide.
SECTION : IV Synthesis and antimicrobial activity of 5-{4'-
[(4''- aryl)-3''- cyano-2''-hydroxy pyridine - 6''-
yl]-phenyl carbamido}-dibenz [b,f] azepines.
Pyridine derivatives of Type : (XII) have been synthesised by the
reaction of  chalcones of Type-(I) with ethyl cyano acetate in presence
ammonium acetate.
PART - VI STUDIES ON CYANO PYRANS
Cyanopyran derivatives have been reported to have various
pharmacological activities like antibacterial, antiviral, antifungal etc. In
order to develop better medicinally important compounds, it was
considered of interest to synthesise some cyanopyran derivatives shown
as under.
SECTION : I Synthesis and antimicrobial activity of 5-{4'-[(2''-
amino)-(4''-aryl)-4'' (H) pyran-3-carbonitrile-6''-yl]
phenyl carbamido}-dibenz [b,f] azepines.
Type (XIII)                          R=Aryl
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Cyanopyaran derivatives of Type (XIII) have been synthesised by
the reaction of chalcones of Type-(I) with malono nitrile in pyridine.
PART - VII STUDIES ON QUINOXALINES
Quinoxlines have been found to possess wide range of
therapeutic activities and industrial importance. These significant
biological properties have aroused considerable interest to design the
compounds in which dibenz [b,f] azpines nucleus is incorporated with a
view to getting compounds with better drug potential.
SECTION : I Synthesis and antimicrobial activity of 2''-Aryl
[(3''-methylphenyl carbamido)-5-dibenz [b,f]
azepine quinoxalines
Quinoxalines derivatives of Type (XIV) have been synthesised by the
reaction of chalcones of Type (I) with bromine in gla. acetic acid and
o-phenylene diamine
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PART : VIII STUDIES ON CYCLOHEXENONES
Various derivatives of cyclohexenones exhibit interesting biological
properties like anticancer, antiinflammatory anticonvulsant, antipyretic etc.
With a view to synthesis more potential drug value compounds. We have
carried out the synthesis of  cyclohexenones derivatives, which have been
represented as under.
SECTION : I Synthesis and antimicrobial activity of ethyl-[(6''-
aryl)-4''-phenyl carbamido}-5- dibenz [b,f] azepine
-2''-oxo cyclohex-3''-ene-1''- carboxalate.
Cyclohexenone derivatives of Type : (XV) have been synthesised of
the cyclocondesation of the chalcones of Type (I) with ethyl acetoacetate
in presence of sodium ethoxide.
PART : IX STUDIES ON BARBITONES
Barbituric acid derivtives showed a wide spectrum of biological
activites. dibenz [b,f] azepine heterocyclic moiety possess diversified
biological properties. Considering all the above facts, it was thought that
barbituric acid group could be introduced to moiety, the resulting
compounds might have some significant biologically active compounds
synthesised, which  have been  described as under.
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SECTION : I Synthesis and antimicrobial activity of 5-{4'-
[(3''-aryl)- 2''- propene - 1'' - barbituric acid] -
phenyl carbamido}-dibenz [b,f] azepines
Barbituric acid derivative of Type (XVI) have been synthesised by
the reaction of chalcones of Type (I) with barbituric acid in gla. acetic
acid.
PART : X STUDIES  ON  THIOSEMICARBOXIMIDES
Thiosemicariboximides derivatives possess broad spectrum of
therapeutic activity like antidiabatic, bactericidal, anticonvalsant,             anti-
pyretic etc. With a view of above facts to synthesised various
thiosemicarboximides derivatives are represented as under.
SECTION : I Synthesis and antimicrobial activity of 5-{4'-
[(3''-aryl)- 2''- propene-1''-thiosemicarboximides]
-phenyl carbamido}-dibenz [b,f] azepine
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Thiosemicarboximes  derivatives of Type (XVII) have been
synthesised by the reaction of the chalcones of Type-(I) with
thiosemicarbazide in alcohol.
The structure elucidation of the synthesized compound have been done
on the basis of element analyses. IR 1HNMR spectroscopy and further sup-
ported by mass spectroscopy. The purity of the synthesised compunds
checked by TLC.
All the compounds have been also evaluted for their antimicrobial
activity towards Gram +ve and Gram -ve bacteria and also evaluated
antifungal activity at a concentration of 50 μg/ml. The antimicrobial
activity of the synthesised compounds have been  compared with known
standard drugs. e.g. ampicillin, chloramphenicol, norfloxacin and gresioflulvin.
12







Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SYNTHESIS, SPECTRAL STUDIES AND
THERAPEUTIC ACTIVITY OF HETEROCYCLIC
 COMPOUNDS
INTRODUCTION
Heterocyclic chemistry has been unparalled progress owing to their
wide natural occurance, specific chemical reactivity and broad spectrum
utility.
Hetrocyclic compounds have great applicability in pharmaceutical,
because they have specific chemical reactivity and provides false synthons
in biosynthetic process.
Some heterocyclic compounds must ideally have a. broad spectrum of
activity with a rapid bactericidal action. We must always continue search
new heterocyclic moleculer and identify its respective drugs activity. To
take the care for synthesis new heterocyclic moleculer a lower toxicity, a
partial or total absence of undesirable side effects, more neutritive value,
improved stability, a decrease in production cost and chek the qualitative or
quantitative improvement in activity with standard drugs. Dibenz [b,f]
azepines derivatives have been reported as a valuable medicine in the treat-
ment anthelmintic, antihistamine activity and also used in the treatment of
parkinson's disease. Dibenz [b,f] azepines substituents serves as nucleus to
a host of compound which are associated with wide spectrum of therapeutic
activity
Heterocyclic compound have great biological significance properties.
(1) They have a specific chemical reactivity.
14
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(2) They resemble essential metabolism and can also provide false synthons
in biosynthetic process.
(3) They fit receptors and block their normal working.
(4) They provide convenient building blockers to which biologically active
substituents can be attached.
The interesting biological activities of heterocycles have stimulated
considerable research work in recent years including to the synthetic utillity.
Heterocyclic compounds can be synthesised by cyclization
reactions(accompanied by elemination of small molecules) addition
reactions; (adduct formation), ring transformation reactions or replacement
involving groups. Formation of heterocycle from acylic compounds alters
the reactivity.
AIMS AND OBJECTIVITS
Poupulation of our country is skyrockating number of diseases are
uncoured eg. cancer, Aids etc.
In the pharmaceutical field, there is a need for new and novel chemical
inhibitors of biological functions. Our efforts are focused on the
introduction of chemical diversity in the molecular frame work in order to
synthesising pharmacologically interesting heterocyclic compounds of widely
different composition. During the course of research work looking to the
applications of heterocyclic compounds, several entities, have been designed,
generated and characterised using spectral studies. The aims and objectives
of the work carried out are as under.
15
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(1) To synthesise pharmacologically active entities like chalcones,
isoxazoles, pyrazolines, pyrimidines derivatives, cyanopyrans,
quinoxalines, cyclohexanones, barbitones, thiosemicarbaximides bear
ing dibenz [b,f] azepines moiety.
(2) To characterize these products for structural elucidation using
spectroscopic technque like IR,1H NMR and Mass spectral studies.
(3) To check the the purity of all compounds using thin layer chromatography.
(4) To evalute these new  products for better drug potential against
different strain of bacteria and fungi activity and compare with known
standard drugs.
The research work is presented as studies on dibenz [b,f] azepines
derivatives are synthesis.
PART - I : STUDIES ON CHALCONES
PART - II : STUDIES ON ISOXAZOLES
PART - III : STUDIES ON PYRAZOLINES
PART - IV : STUDIES ON PYRIMIDINE DERIVATIVES
PART - V : STUDIES ON CYANO PYRIDINES
PART - VI : STUDIES ON CYANO PYRANS
PART - VII : STUDIES ON QUINOXALINES
PART - VIII : STUDIES ON CYCLOHEXENONES
PART - IX : STUDIES ON BARBITONES
PART - X : STUDIES ON THIOSEMI CARBOXIMIDES
16
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PART - I
STUDIES ON CHALCONES
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
STUDIES ON CHALCONES
INTRODUCTION
The chemistry of chalcones (M) have generated intensive scientific
studies throughout the world specially interesting are their biological and
industrial applications. Chalcones are coloured compounds because of the
presence of the chromophore, auxochromes. They are known as
benzalacetophenones or bnzylidene acetophenones. S.V. Kostanecki and
J. Tambor1 gave the name chalcone".
Chalcone are characterised by their possession of a structure in which
two aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chlacones are phenyl styryl ketones,
benzalacetophenones. β-phenyl acrylphenone, γ-oxo-α-γ-diphenyl-α-propyl-
ene and α-phenyl-β-benzoethylene.
SYNTHTIC ASPECT:
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient method is one that involves the
Claisen-Schmidt condensation of equimolar quantities of an aryl methyl ketones
with aryl aldehyde in presence of alcoholic alkali.2
18
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Several condensing agents used are alkali of different strength3-4, hydrogen
chloride5,6 ,Phosphorous oxychloride7, Piperidine8, anhydrous Aluminium
choride9, Boron trifluoride10, aqueous solution of  borax11, amino acid12 and
perchloric acid13 etc.
MECHANISM:
Chalcone formation proceeds through aldol type of condensation and
the process is catalysed by the presence of alkali14, following steps of the
reaction mechanism are as under.
The intermediate Aldol type of products formed readily undergoes
dehydration even under mild condition, particularly when R and R' are aryl
groups.
REACTIVITY OF CHALCONES:
The chalcone have been found to be useful for the synthesis of variety
of heterocyclic compounds are as under.
(a) Pyrazolines15 and its derivatives can be prepared by the condensation
of chalcones with hydrazine hydrate and acetic acid.
(b) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines16.
(c) Isoxazoles17 can be prepared by the treatment of chalcones with
19
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hydroxylamine hydrochloride and sodium acetate.
(d) Chalcone on condensation with malononitrile in pyridine forms 2-amino
3-cyanopyrans.18
(e) Chalcones on treatment with urea in presence of alkali affords 2-oxo
Pyrimidines19
(f) Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thiopyrimidines.20
(g) Chalcones on treatment with guanidine hydrochloride in presence of
alkali affords 2-amino pyrimidines.21
(h) Chalcones reacts with P2S5 yielding 2-isothiazolines.
22
(i) Chalcones with sodium nitrile in presence of glacial acetic acid in
ethanol produces 2-(H)-pyrimidines.23
(j) Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines.24
(k) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-
thiazepines.25
(l) Chalcones on reaction with semicarbazide hydrochloride in ethanol
affords 1-caroxamide pyrazolines.26
(m) Chalcones on reaction with 2-aminopyrimidine in glacial acetic acid
affords pyrido pyrimidines.27
(n) Oxiran28 can be prepared by the reaction of chalcone with H2O2 in
basic media.
(o) Cyanopyridone29 derivatives can be prepared by the condensation of
Chalcone with ethalcyanoacetate.
(p) Chalcones gives imine derivatives with amine in presence of sulphuric
acid as a catalyst.30
(q) Chalcone on reaction with barbituric acid gave barbitone derivatives.31
20
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
THERAPEUTIC INTEREST:
Chalcones are potential biocides, some naturally occuring antibiotics
and aminochalcones probably own their biological activity to the presence














Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by S.R. Modi et al.50 and A. Attia51, V. R.
Mudalir et al52 have prepared phenoxy chalcones and observed their
insecticidal activity. Kammei et al53. have been synthesised phenoxychalcones
and observed their insecticidal activity. R. De vincenzo et al54. and Han et al.55
have chalcone derivatives for their anti-inflammatory activity. Okuyana et al56.
have been reported chalcone derivatives reductase inhibitor activity. Antitumor
and antifungal activity as reported by A. Tsotitus and co-worker57. Antifeedant
activity of chalcones have been observed by P. N. Sharma and Sreenivasulu58.
21
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Ezio Bombardelli et al59. have demonstrated that chalcone possess a
valuable antiproliferation activity both on sensitive cancereous cell and on
cell which are resistant to common chemotherapeutic drugs. S.Elichi etal. of
the have been patented chalcones for their use for treatment of glaucoma60.
B. B. kailashnikov etal61. and S.Santoshi etal62 showed antifungal activity,
P. Walavalker etal63. showed aldose reductase inhibitor, O. tory etal64
evaluated anticancer activity, and J. R. Dimmock. et al65 and T.M.
Abdelr rahman66 evaluated antimicrobial activity.
Recently, Ni Liming et al.67 have synlhesised chalcones and screened
for heir their antiinflammatory and cardiovascular activity. Kumar Srinivas et
al68. have synthesised chalcones as a antitumor agent. Ko Horng Huey et al69.
have prepared chalcones as antiinflammatory agent. Nakahara Kazuhiko et
al70. have synthesised chalcones as carcinogen inhibitors. Antitubercular agents
of chalcone.
Lin Yah meei et al71 have synthesis chalcones derivatives.
B. R. Das et al72. have found that chalcones possesses larvicidal
properties. Kirm Min Young et al73. have synthesised chalcones and tested
for their matrixmetalloproteinase inhibitor activity.
Liu Mei et al74. have been prepared chalcones and evaluated  antimalarial
activity. O. veronika et al75, have synthesised chalcones and screened as car-
diovascular agent.
Moreover, it has been found that chalcone derivatives possesses nitric oxide
inhibitor76,77 and anti-HIV78,79 activities.
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Chalcone bearing a very good synthon, variety of novel heterocycles
with good pharmacological profile can be designed. These valid
observation led us to explore chalcone chemistry by synthesizing several
derivatives like isoxazoles, pyrazolines, pyrimidine, bearing different
heterocyclic ring systems for medicinal Value, in order to achieving better
therapeutic agents, this study described as under.
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-[(3"-
ARYL)-2"-PROPENE-1"-ONE PHENYL CARBAMIDO}-DIBENZ
[b,f] AZEPINES.
Recently much interest has been focoused on the synthesis and
biodynamic activities of chalcones and it is a good synthon for various
heterocyclic rings, with a view to obtained compounds havings better thera-
peutic activity 5-{4"-[(3"-aryl)-2" propene-1"one] phenyl carbamido} - dibenz
[b,f] azepines have been synthesis by the condensation of 5-{4' acetyl phe-
nyl carbamido}-dibenz [b,f] azepines with aromatic aldehyde in presence of
alkali. The latter was 5-{4'-acetyl phenyl carbamido}-dibenz [b,f] azepines
have been synthesis  by the condensation of 5- dibenz [b,f] azepines methanoyl
chloride with 4-aminoacetophenone.
The constitution of the synthesised products have been characterised
by elemental analysis, IR,1H NMR and Mass spectra study. The product were
screened for antimicrobial activity at a concentration of 50 μg








































































































IR SPECTRAL STUDY OF 5-{4'-[3"-(4"'-METHOXYPHENYL)-2"-

















































































Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer frequency range : 4000-
400 cm-1 (KBrdisc)
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NMR SPECTRAL STUDY OF 5-{4'-[3"-(4"'-METHOXYPHENYL)-2"-
PROPENE-1"-ONE] PHENYL CARBAMIDO} - DIBENZ [b,f] AZEPINES.






















































































































































































































































































































































































































































































































































































   
   















































































































Type : (I) R = Aryl




(A) Synthesis of 5-(4'-Acetylphenyl carbamido)-dibenz [b,f] azepines.
A mixture of 5-dibenz [b,f] azepines methanoyl chloride (2.55g, 0.01M),
4-amino acetophenone (1.35g, 0.01M) in ethanol (25 ml) and pyridine (5 ml)
was refluxed on a oil bath at 120oC at 12 hrs. The content was cooled and
poured into crushed ice, filtered and washed with water. The isolated product
was crystallized from ethanol yield 85.42 %, M.P :170oC (Found : C:77.85,
H: 5.02; N: 7.82, C23 H18N2O2  required C: 77.96; H : 5.08; N : 7.90 %)
(B) Synthesis of 5-{4'-[3"-(4'''-methoxy phenyl)-2"-propene-1"-one]-
phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5- (4'-Acetyl phenyl carbamido)-dibenz [b,f] azepines (3.54
g, 0.01M), 4-methoxy benzaldehyde (1.36g, 0.01M) ethanol 40% NaOH till
the solution vigorously stirring at basic medium at 24 hrs. The contents were
poured into ice, acidified filtered and crystallized from ethanol yield 79.86%
M.P. 105oC, (found : C : 75.80; H:5.01; N:5.80; C31 H24 N2O3 required : C:
75.86; H:5.08; N: 5.93%)
Simillary other chalcones were prepared and their physical data are
recorded in table No. 1
(C) Antimicrobial activity of 5-{4'-[(3"-Aryl)-2"-propene-1"-one]-
phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as  described in part : I,
section: I, page No. : 32-34
The zone of inhibition of the test solution are recorded in Table No. : 1
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(D) Antimicrobail activity of 5-(4'-Acetylphenyl carbamido)-dibenz
[b,f] azepines.
Method: It was carried out using the cup-plate method which has been
described as under.
Antibacterial activity : 80
The purified products were screened for their antibacterial activity. The
neutrient agarbroth prepared by the usual method, was inoculated specially
with 0.5 ml for 24 hours, old subsclture of B. megaterium S.aureus,
Escherichia coli, S. taphimarium, in separate conical flasks at 40-50°C and
mixed well by gentle shaking. About 25 ml of the contents of the flask were
poured and evenly spread in a petridish (13 cm in diameter) and allowed to
set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer
in a agar medium and filled with 0.10 ml (1.0 μg/ml) solution of sample in
dimethyl formamide.
The plates were incubated at 32°C for 24 hrs. and the control was also
maintained with 0.1 ml of DMF in similar manner and the zone of inhibition
of the bacterial growth are measured in mm diameter and are recorded in
Table No. A.
Antifungal activity 81
Aspergillus niger was employed for testing fungicidal activity using
cup-plate method the cultures were maintained on subouraud's agar slants.
Purified compounds were used for testing the fungicidal activity, sterlised
subouraud's agar medium was inoculated with 72 hours old 0.5 ml suspen-
sion of fungal spores in a sterilised separate flask. About 25 ml of the inocu-
lated medium was evently spreaded in a petridish and allowed to set for 2 hrs.
The cups (10 mm in a diameter) were punched in petridish and loded with 0.1
ml (1.0 mg/ml) of solution of a sample in DMF
32
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The plate were incubated at room temp. 37° C for 48 hrs. After the
completion of incubation period. The zone of inhibition or growth in the form
of diameter in mm was measured. Along the test solution in each petridish one
cup was filled up with solvent acts as control. The zone of inhibition are
recorded in Table No. A.
ANTIMICROBIAL ACTIVITY
Product : 5-(4'-Acetylphenyl carbamido)-dibenz [b,f]
azepines.
Method : Cup Plate
Gram Positiv Bacteria : B. megaterium
S.aureus,
Gram Negative Bacteria : Escherichia coli,
S. taphimarium,
Fungi : Aspergillus niger
Concentration : 50 μ g
Solvent : Dimethyl formamide
Standard Drug : Ampicillin, Chloramphenicol, Norfloxacin,
Greseofulvin
The antibacterial activity was compared with standard drugs viz.
Ampicillin, Chloramphenicol, Norfloxacin and antifungal activity was com-
pared with standard drug viz. Greseofulvin. The Zones of inhibition were
measured in mm. The Zones of inhibition that displayed by standard drugs
are recorded in Part - I, Page No. 34
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STUDIES ON ISOXAZOLES
INTRODUCTION
Isoxazoles-(N) are a group of heterocyclic compounds containing two
hetero atoms : oxygen and nitrogen.
In 1888 claisen first suggest in isoxazoles (N) for a product from the
reaction of 1,3 diketone with hydroxylamine82 subsequently a solid
foundation for the chemistry of isoxazoles was laid down by claisen and his
students. It was shown to possess typical properties of an aromatic system
but under certain reaction conditions, particularly in reducing or basic
media, it becomes very highly labile. The next important contribution to the
chemistry of isoxazoles was made by Quelico in 1946 when he began to
study the formation of isoxazoles from nitrile N-oxides and unsaturated com-
pounds.83
SYNTHETIC ASPECT:
Isoxazole may be prepared by the reaction between hydroxylamine and
α,β (3-unsaturated compounds the reaction proceeds Via the formation of an
oxime. which possibiy undergoes cyclization.
38
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Isoxazole can be prepared by various methods which are described as
under. L.S. Crawly etal84 prepared isoxazole from chalcones hydroxylamine
hydrochloride and KOH in methanol.
THERAPEUTIC IMPORTANCE
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B.Maggio et al111 synthesised  novel.  3-(isoxazol-3-yl)-quinazolin-4-(3H)-
one derivatives and tested for their analgesic and antiinflammatory activities,
as well as for their acute toxicity and ulcerogenic effect. Some of them had a
very low ulcerogenic effect.
C. B. Xue et al112 reported the replacement of the benzamide in XUO57
(potent inhibitor) with an isoxazole carboxamide resulted in significant
improvernent in vitro potency. More importanty the analogue XXUO65
showed on excellent oral antiplatelet effect in dogs.
M. Masui et al.113 have prepared isoxazoles having pesticidal activity.
Some excellent herbicidal results obtained by K.V. Reddy et al.114 Moreover
isoxazoles found to possess remarkable anxiolytic and antihypenensive
effect, reported by J. Nyitrai et al.115, A. Mishra et. al.116 have synthesised and
reported isoxazoles as useful agents for analgesic and antiinflammatory
activities. T. D. Aicher et al.117 cited some isoxazole derivatives possessing
hypoglycemic agents.
S. Ozkan et al.118 have prepared 3-(l-phenyl-l,2,3-triazol-4-yl)
benziscreazoles (O) and studied their insecticidal acitvity.
40
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M. Dauria119 studied photochemical behaviour of isoxazole derivatives.
Y. N. Manohara et al.120 investigated thermal decomposition kinetics of Co
(II) and Ni (II) complexes of substituted isoxazole and their antibacterial
activity. A.R. Parikh and co worker121 have prepared isoxazole derivatives
and documented antitubercular activity. Some isoxazoles are found to
possess herbicidal122-124 Potential anti-inflammatory125,126 and antimicrobial
agents127,128 estrogen receptor modulators129 and inhibitor of P38  MAP kinose
activities.130
N. Lal et al.131 have synthesised isoxazole derivatives (P) and reported
their adrenergic antagonist activity.
When an intension of the compounds possessing better therapeutic
activity we have undertaken the synthesised of isoxazoles bearing Dibenz
[b,f] azepines moiety which have been described as under.
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-[(5"-
ARYL)-ISOXAZOLE-3"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f]
AZEPINES.
Taking into consideration of wide therapeutic activity of isoxazole
derivatives. The synthesis of  5-{4'-[(5"-aryl) -isoxazole 3"-yl]-phenyl
carbamido}-dibenz [b,f] azepines have been synthesised by the
condensation of 5-{4'-[(3"-aryl)-2"- propene -1"-one] phenyl carbamido}-
dibenz [b,f] azepines with hydroxyamine hydrochloride.
The constitution of the products have been characterised by elemental
analyses, IR,1H NMR and Mass spectral study. The product were screened
for antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, section : I, Page No.32-34

























































































































































































Intrenal standard : TMS; solvent :CDCl3 : Instrument : BRUKER spectrometer
(300 MHz)

































































































































































































































































































































































































































































































































































































































































































































40% NaOH, 24 hrs., Stirring




(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepines.
. For synthesis see part-I, section : I ,Page No. : 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: 1, section : I, Page  No : 31
(c) Synthesis of 5-{4'-[5"-(4"'-methoxy phenyl)-isoxazole-3"-yl]
phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine . (4.72g,0.01M); hydroxy
amine,hydrochloride (0.69g, 0.01M) and ethanol (20 ml.). The reaction mix-
ture was reflux at 120OC for 5 hrs. The reaction mixture was cooled, poured
into crushed ice, filtered, dried. The isolated products was crystallised from
ethanol, yield 72.68%; M.P. 120OC ,(Found:C, 76.65 ; H, 4.70 ; N, 8.60
C31H23N3O3  required C , 76.70 ; H, 4.74 , N, 8.65 %).
Similary other isoxazoles were synthesised and their physical data are
recorded in table No. : 3
(D) Antimicrobial activity of 5-{4'-[(5"-aryl)-isoxazole-3"-yl] phenyl
carbamido}-dibanz [b,f] azepines.
Antimicrobial testing was carried out as described in part : I,
section: I ,Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. : 4
49
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STUDIES ON PYRAZOLINES
INTRODUCTION
Amongst nitrogen containing five membered heterocycles, pyrazolines
(Q) have proved to be the most useful frame work for biological activities,
pyrazolines have attracted attention of medicinal chemistry for both with
regard to heterocyclic chemistry and the pharmacological activities
associated with them in 1967 Jarobe, reviewed the chemistry of pyrazolines,
which have been studied extensively for their132-133 and industrial
applications.
SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyrazoline derivatives
documented in literature are as follows.
(1) 2-pyrazolines can be constructed by the cyclocondensntion of chalcones
with hydrazine hydrate.134
(2) 2-Pyrazoline can also be prepared by the condensation of chalcone
dibromide with hydrazines.135
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(3) 2-Pyrazolines can be synthesised by the cycloaddition of diazomethane
to substituted chalcone.136
(4) Dipolar cycloaddition of nitrilimines of dimethyl fumarate fumaronitrile
and the N-aryl maleimides yields the corresponding pyrazolines.137
(5) Epoxidation of chalcones have epoxy kelones which reacted with
hydrazine and phenyl hydrazine to give pyrazolines.138
Furthermore, B. Gyassi et al.139 investigated the one pot synthesis of
some and pyrazolines in dry media under microwave irradiation S. Paul et.
al.140 D. Dandia et.al.141 have also described the microwave assiled synthesis
of 2-pyrazolines.
MECHANISM:
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate.142
Nucleophilic attack by hydrazine at the β-carbon of the α−β
unsaturated carbonyl system forms species (II) in which the-ve charge is
mainly accomodated oy the electro nagative oxygen atom.
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Proton transfer from the nitrogen to -ve oxygen produces an
intermediate enol which simultaniously ketonise to ketoamine (III). Another
intramolecular nucleophilic attack by the primary amino group of ketoamine
on its carbonyl carbon followed by proton transfer from nitrogen to oxygen
leads ultimately to amine (IV). The later with a hydroxy group and amino
group on the carbon lose water moleculer to yield the pyrazolines.
THERAPEUTIC IMPORTANCE:
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S. S. Sonarc et al.163 have synthesised-3-(2-acetoxy-4-methoxy phenyl)-
5-(substituted phenyl)-pyrazolines (R) and tested their antimicrobial activity.
Moreover, T. M. Stivenson el al.164  have also investigated N-subsliluled
pyrazoline type insecticides, T. Katsuhori165 have patented pyrazoline
derivatives as herbicides and K. Johannes, et. al.166 as insecticides. Z. Moritaz
and S. Hadol167 to investigated a semi emperial molecular orbital study on the
reaction of aminopyrazolinyl azodye with singlet molecular oxygen.
M. K. Shivnanda and co-worker168 have prepared pyrazolines and
reported their antibacterial activity. B. Shivarama Holla et. al.169-170 have
sunthesised pyrazolines as antibacterial agent. S. P. Hiremath et al.171 have
synthesised pyrazolines as analgesic, antiinflammatory and antimicrobial
agent. V. Malhotra et. al.172 have synthesised new pyrazolines as a
cardiovascular agent.
Ji-Inkim Almstead et. al.173 have prepared pyrazolines as vascularization
agent.Guniz Kucukguzel et. al.174 have synthesised pyrazolines as a
antimicrobial and anticonvulsant agents.
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T. Z. Gulhan and co-workers175 have prepared pyrazolines as a
hypoiensive agent. S. Sharma et. al.176  have synthesised pyrazolines and
tested their antiinflammatory activity. Ashok Kumar et. al.177 have
synthesised pyrazolines as anticonvulsant agent B. Jayshankara et al.178 have
synthesised pyrazoles and screened for their epilepsy activity.
In view of therapeutic activities shown by pyrazolines, it was
contemplated to synthesis some new pyrazolines in search of agent
possessing higher biological activitiy with least side effect have been
described as under.








SECTION-III SYNTHESIS AND ANTIMICROBIAL ACTIVITY
OF 5-{4'-[(5"-ARYL)4",5"-DIHYDRO-1"N-PHENYL
PYRAZOLE -3"-YL] PHENYL CARBAMIDO}-
DIBENZ [b,f] AZEPINES.
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-[(5"-
ARYL)-4",5"-DIHYDRO-1"(H)PYRAZOL -3"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES
Pyrazoline derivatives posses broad spectrum of pharmabiological
activity which are reflected by their use as analgesic, antiinflammatory,
anticonvalsant, antimicrobial and antipyretic agents. prompted by above facts
5-{4'-[(5"-aryl)-4",5"-dihydro-1"-(H)-pyrazol-3"-yl]-phenyl carbamido}-
dibenz [b,f] azepines type (III) have been synthesised by the condensation of
5-{4'-[(3"-aryl) 2"-propene-1"-one]-phenyl carbamido}-dibenz [b,f] azepines.
with hydrazine hydrate.
The constitution of the synthesized products were supported by IR, 1H,
NMR and Mass spectral study. The products were screened for their
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, section : I, Page No. : 32-34














































































































































































































Intrenal standard : TMS; solvent :CDCl3 : Instrument : DPX-200 Spectrometer
(200MHz)
NMR SPECTRAL STUDY OF 5-{4'-[5"-(4'''-METHOXY  PHENYL)-
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EXPERIMENTAL
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-(5"-
ARYL)-4",5"-DIHYDRO-1"-(H)-PYRAZOL-3"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido}-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No.: 31
(B) Synthesis of 5-{4'-[3"-(4"'-Methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: 1 section : I  Page No : 31
(c) Synthesis of 5-{4'-[5"-(4"'-methoxy phenyl)-4",5" dihydro-1"(H)
pyrazlo-3"-yl] phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72.g 0.01M); hydrazine hydrate
(1.0ml) in methanol (15ml) was refluxed for 12 hrs. The product was poured
into crushed ice filtered, washed with water and crystallised from dioxane
yield : 78.68 % M.P. 60oC (Found : C 75.40; H: 5.23; N: 11.50, C31H26N4O2
Required : C 76.54; H: 5.34; N: 11.52 %)
Simillary other pyrazole derivatives have been synthesised and their
physical data are recorded in Table No. : 5
(D) Antimicrobial activity of 5-{4'-[(5" aryl)-4",5"- dihydro -1"-(H)
pyrazol-3"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 6
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SECTION : II
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(5"-
ARYL)-4",5"-DIHYDRO-1"N-ACETYLPYRAZOL-3"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Acetyl pyrazoline derivatives procuring better therapeatic and
antimicrobial activity looking at their versatile therapeutic importance and
with an aim to getting better drug, it was considered worthwhile to synthesis
some new pyrazoline. The synthesis of 5-{4'-[(5"-aryl)-4"-5"-dihydro-1"-
acetyl pyrazol-3-yl]-phenyl carbamido}-dibenz [b,f] azepines have been syn-
thesis by the cyclocondensation of chalcones of type: (I) with hydrazine
hydrate and glacial acetic acid
The constitution of the  products  have been characterised by elemental
analyses IR,1H NMR and Mass spectral study. The products were screened
for their antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, section I, Page No. 32-34
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Intrenal standard : TMS; solvent :DMSO: Instrument : BRUKER Spectrometer
(200MHz)




































































































































































































































































































































































































































































































































































































































































































































































































40% NaOH, 24 hrs. Stirring
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EXPERIMENTAL
SYNTHESIS OF 5-{4'-(5"-ARYL)-4",5"-DIHYDRO-1"-N-ACETYL PYRAZOL-
3"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f]-AZEPINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-Methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I,  section : I, Page No : 31
(c) Synthesis of 5-{4'-[5"-(4"'-methoxy phenyl)-4"-5"-dihydro-1"-N-
Acetyl pyrazol-3"-yl]-phenyl carbamido} dibenz [b,f] azepines.
A mixture of 5-{4'-[5"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72.g,0.01M); hydrazine hydrate
(1.0ml), glacial acetic acid (2.0 ml) and methnol (20 ml) was refluxed for 12
hrs. The reaction mixture is poured into crushed ice, filtered, washed with hot
water and crystalised from dioxane yield : 78.68 % M.P. 68OC (Found :
C:74.85; H: 5.14; N:10.45; C33H28O3N4 Required : C:75.00; H: 5.30; N: 10.60 %)
Simillary other acetyl pyrazolines have been synthesised and their
physical data are recorded in Table No. : 7
(D) Antimicrobial activity of 5-{4'-[(5"-aryl)-4",5"- dihydro -1"-N-
acetyl pyrazole-3"-yl]-phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I, Page No. : 32-34
The zone of inhibition of the test solution are recorded in Table No. : 8
75
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SECTION : III
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(5"-
ARYL)-4",5"-DIHYDRO-1"-N-PHENYL PYRAZOLE-3"-YL]-
PHENYL CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Looking to the interesting therapeutic activities of pyrazoline, it was
considered worth while  to synthesize compounds bearing 5-{4'-[(5"-aryl)-
4"-5"-dihydro-1"-phenyl pyrazole-3"-yl]-phenyl carbamido}-dibenz [b,f]
azepines. of Type (V) have been synthesis 5-{4'-[(3"-aryl)-2"-propene-1"-
one]-phenyl carbamido}-dibenz [b,f] azepines with phenyl hydrazine.
The constitution of the  products  have been characterised by elemental
analyses IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg.
The details have been cited in the part : I, section I, Page No. : 32-34























IR  SPECTRAL STUDY OF-5-{4'[5"-(4"'-METHOXY PHENYL)-
4",5"-DIHYDRO-1"-N-PHENYL PYRAZOL-3"-YL]-PHENYL
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Intrenal standard : TMS; solvent :CDCl3: Instrument : BRUKER Spectrometer
(200MHz)
NMR SPECTRAL STUDY OF-5-{4'[5"-(4"'-METHOXY PHENYL)-
4",5"-DIHYDRO-1"-N-PHENYL PYRAZOL-3"-YL]-PHENYL













































































































































































































































































































































































































































































































































































































   
   













    







    
    








    
    
    
















































































































































40% NaOH, 24 hrs stirring
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(5"-ARYL)- 4",5"-DIHYDRO-1"-N-PHENYL
PYRAZOL-3"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f]-
AZEPINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No.: 31
(B) Synthesis of 5-{4'-[3"-(4"'-Methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: 1 section : I, Page  No : 31
(c) Synthesis of 5-{4'-[5"-(4"'-methoxy phenyl)-4"-5"-dihydro-1"-N-
phenyl pyrazol-3"-yl]-phenyl carbamido} dibenz [b,f] azepines.
A mixture of 5-{4'-[5"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72.g,0.01M); phenyl hydrazine
hydrate (1.0ml) and methanol (20 ml) was refluxed for 12 hrs. The reaction
mixture is poured into crushed ice, filtered, washed with hot water and crys-
talised from dioxane yield : 62.78 % M.P. 70OC (Found : C:78.74; H: 5.20;
N:9.88; C37H30O2N4 Required : C:79.00; H: 5.33; N: 9.96 %)
Simillary other phenyl pyrazolines have been synthesised and their physical
data are recorded in table No. : 9
(D) Antimicrobial activity of 5-{4'-[(5"-aryl)-4",5"- dihydro -1"-N-
phenyl pyrazole-3"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 10
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Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
STUDIES ON PHYRIMIDINE DERIVATIVES
INTRODUCTION
Pyrimidine derivatives occur in natural products179  like nucleic acid
and vitamin-B have remarkable pharmaceutical importance because of thier
biological180-183 several analogs of nucleic acids have been used as compound
that interfere with the synthesis and functioning of nucleic acids, and
example is fluorouracil which has been used in cancer treatment. Pyrimidines
are among those molecules that make life possible as being same of the
building blocks of DNA and RNA.
Some pyrimidines of physiologically as well as pharmacologically
importance are as under : e.g. cytosine, beclmeihrin(S), blasticidin (T).
Synthetic pyrimidine derivatives contribute much to the searchable
literature of pyrimidine derivtives, in huge libraries owing to their wide
applicability in different fields.
SYNTHETIC ASPECT:
Different methods for the synthesis of pyrimidine have been cited in
the literature.184
1. F. Bigi and co-worker185 have synthesised as shown below under
solvent free condition.
89
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MECHANISM :
The reaction of α,β - unsaturated system with urea to the formation of
4-oxo-pyrimidine by 1,2 and 1,4 michal addition.
90
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THERAPEUTIC IMPORTANCE
Pyrimidine derivatives have proven to be of great importance in
exhibiting and enhancing the biological activities such as.
(a) Antitumor186
(b) Carcinostatic187










Moreover, L. V. Azarayan et al.210 have synthesised pyrimidine diones as
antitumor agent. V. P. Krivongov and co-worker211 have synthesised
pyrimidinone derivatives possessing immunotropic and antiinflammatory
activitiy. M. Refai and co-worker212 have prepared some new pyrimidine de-
rivatives showed moderate activity against the growth of Bacillus substilis,
Staphylococus aureus and Aspergillus niger. A. Kofies et. al.213 have
seggested that pyrimidinone (UV) as herbicidal and plant growth
regulators.
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K. Mogilaiah214 have prepared spiropyrimidinones as antibacterial. M.
wilhelm215 have synthesised pyrimidinones as herbicidal agents.
C. D. Timothy and co-worker216 have suggested imidazolyl pyrimidinones
as antiviral T. Nagamatsu et. al.217 have prepared some new triazolo [3,4-c]
pyrimidine as xanthin oxidase inhibitors. A. Roland et. al.218 have prepared
oxazolyl uracil as herbicidal and insecticidal. M. M. Yari and co-worker219
have investigated the pyrimidinone derivatives which possess calcium
antagonist activity.
M. A. Bruce and co-worker220 prepared The dihydropyrimidinones as
NPY antagonist.
D. R. Sidler221 have reported pyrimidinone derivatives, useful as an α-
adrenergic receptor antagonist.
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Mona Mahram and co-worker222 have synthesied pyrimidine derivatives
as potent antimicrobial and antitumor agents.
K.A. Gupta and co-worker223 have prepared 2,6-disubstituted
pyrimidinones as CNS agent.
Pyrimidinone derivatives 224-225 have found to be calcium channel blocker
M.M.Barbuliene et. al.226 have synthesised pyrimidinones as antiinflammatory
agent.
Recently. Amjad Ali et. al.227 have synthesised new fused pyrimidinones
as antimicrobial agents. Abd El-Galil et. al.228 have synthesised pyrimidine
as androgenic, anabolic and antiinflammatory agents, martin Bolli et.al.229
have synthesised pyrimidines as endothelin receptor antagonists. G. Z. Hang
et. al.230 have synthesised and screened for their leukocyte functions inhibitor
activity. yamamo to et al.231 have synthesised pyrimidines and tested their
hyderproliferative disorder activity. Adenosine receptor antagonist
pyrimidinones have been prepared by Tsytsumi Hideo et. al. 232
93
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SECTION : III SYNTHESIS AND ANTIMICROBIAL ACTIVITY




Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(6"-ARYL)
2"-MERCAPTO-3"-4"-DIHYDRO PYRIMIDINE-4"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Looking to the interesting pharmacological and agricultural  activity of
pyrimidine ring system, it was considered worthwhile to synthesise
compounds bearing phenyl carbamido dibenz [b,f] azepine nucleus linked to
the pyrimidine nucleus 5-{4'-[(6"-aryl)-2"-mercapto-3"-4"-dihydro pyrimidine-
4"-yl] phenyl carbamido}-dibenz [b,f] azepines have been synthesis by the
condensation of 5-{4'-[(3"-aryl)-2"-propene-1"-one] phenyl carbamido}-
dibenz [b,f] azepines of Type (I) with thiourea  in presence of catalytic amount
of alcoholic pottasium hydroxide.
The constitution of the  products  have been characterised by elemental
analyses IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, section : I, Page No. 32-34





































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Internal standard : TMS; solvent :CDCl3: Instrument : BRUKER Spectrometer
(300MHz)
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 40% NaoH, 24 hrs Stirring















(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine.
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propen-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: 1 section : I , Page No : 31
(C) Synthesis of 5-{4'-[6"-(4"'-methoxy phenyl)-3"-mercapto 3"-4"-
dihydro pyrimidine -4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepine. (4.72.g, 0.01M) and thiourea (0.66g,
0.01M) was refluxed at 90oC for 14 hrs. in presence of basic medium like
alcoholic KOH and methanol. The reaction mixture was poured in to crushed,
ice, filtered and dried. The product was  isolated, and crystalised from dioxane
yield : 68.71, % M.P. 80oC (Found : C : 70.08;  H: 4.88;  N:10.52; C32H26N4SO2
Required : C; 70.18; H; 4.90; N; 10.56 %)
Simillary other compounds were prepared an their physical data are
recorded in table No. : 11
(D) Antimicrobial activity of 5-{4'-[(6"-aryl)-2"mercapto 3",4"-
dihydro-pyrimidine-4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I, Page No. 12
The zone of inhibition of the test solution are recorded in Table No.12
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Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SECTION : II
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(6"-ARYL)
2"-HYDROXY-3",4"-DIHYDRO PYRIMIDINE-4"-YL] PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES
Looking to the interesting pharmacological and agricultural activity of
pyrimidine ring system, it was considered worthwhile to synthesis
compounds bearing phenyl carbamido dibenz [b,f] azepine nucleus linked
to the pyrimidine nucleus 5-{4'-[(6"-aryl)-2"-hydroxy-3",4"-dihydro pyrimidine
4"-yl] phenyl carbamido}-dibenz [b,f] azepines of type (VII) have been
synthesised by the condensation of 5-{4'-[(3"-aryl)-2"-propen-1"-one]
phenyl carbamido}-dibenz [b,f] azepines one of Type-(I) with urea in
presence of catalytic amount of conc. HCl.
The constitution of the  products  have been characterised by elemental
analyses IR, 1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, section I, Page No. 32-34
























IR SPECTRAL STUDY OF 5-{4'-[6-(4'"-METHOXY PHENYL]- 2"-
















Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer frequency range : 4000-





























































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :DMSO: Instrument : DPX-200 Spectrometer
(200MHz)
























































































































































































































































































































































































































































































































































































































    
    








    
    








































































































40% NaOH, 24 hrs Stirring















(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propen-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: 1, section : I, Page No : 31
(C) Synthesis of 5-{4'-[6"-(4"'-methoxy phenyl)-2"-Hydroxy 3"-4"-
dihydro pyrimidine -4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and urea (0.60g,
0.01M) was refluxed at 90oC for 14 hrs. in presence of acid catalyst like HCl
in methanol the reaction mixture was poured into crushed ice, filtered and
dried the product was isolated, crystallised from dioxane: yield : 70.19 %
M.P. 112OC (Found:C:74.60; H: 5.01; N: 10.81; C32H26N4O3
Required: C:74.70; H: 5.05; N: 10.89 %)
Simillary other pyrimidine derivatives have been synthesised and their
physical data are recorded in table No.: 13
(D) Antimicrobial activity of 5-{4'-[(6"-aryl)-2"-hydroxy 3",4"-
dihydroxy pyrimidine-4"-yl] phenyl carbamido}-dibenz [b,f]
azepines.
The antimicrobial testing was carried out as described in part : I,
section: I Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 14
112


























































































































































































































































































































































































































































































































































































































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SECTION : III
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(6"-ARYL)
2"-AMINO-3",4"-DIHYDRO PYRIMIDINE-4"-YL] PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Looking to the interesting pharmacological and agricultural activity of
pyrimidine ring system, it was considered worthwhile to synthesis
compounds bearing phenyl carbamido dibenz [b,f] azepine nucleus linked
to the pyrimidine nucleus 5-{4'-[(6" aryl)-2"-amino-3",4"-dihydro pyrimidine
4"-yl] phenyl carbamido}-dibenz [b,f] azepines of type (VIII) have been
synthesised by the condensation of 5-{4'-[(3"-aryl)-2"-propene-1"-one] phe-
nyl carbamido}-dibenz [b,f] azepines  of Type (I) with guanidine hydrochlo-
ride in presence of alcohol potassium hydrochloride.
The constitution of the  products  have been characterised by elemental
analysis IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, section I, Page No. 32-34
































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :DMSO: Instrument : DPX-200 Spectrometer
(200MHz)




































































































































































































































































































































































































































40% NaOH, 24 hrs Stirring
Guanidine Hydrochloride
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(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I section : I, Page No : 31
(C) Synthesis of 5-{4'-[6"-(4"'-methoxy phenyl)-2"-amino 3"-4"-
dihydro pyrimidine -4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one] henyl
carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and guanidine
hydrochloride (0.95g, 0.01M) was refluxed at 110oC for 12 hrs. in presence
of alco-KOH in methanol the reaction mixture was poured into crushed ice,
filtered and dried the  product was  isolated, crystallised from dioxane: yield
:69.71 % M.P. 89OC (Found:C:74.62; H: 5.40; N:13.44; C32H27N5O2
Required: C:74.70; H:5.44; N: 13.61 %)
Simillary other pyrimidine were synthesised and their physical data are
recorded in Table No. 15
(D) Antimicrobial activity of 5-{4'-[(6"-aryl)-2"amino-3",4"- dihydro-
pyrimidine-4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
Antimicrobial testing was carried out as described in part : I, section: I
Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 16
122

















































































































































































































































































































































































































































































































































































































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
STUDIES ON CYANO PYRIDINES
INTRODUCTION
Pyridine and its derivatives represent one of the most active class of
compounds possessing a wide spectrum of biological activities in the field
of medicine, agriculture and industrial chemistry. Pyridine-3-carboxamide
occurs as a component of the structure of the important coenzymes NADP +,
one of the B12 complex of vitamins, occurs in red blood corpuscles and
participates in biochemical redox reaction. Pyridoxol (Vitamin B6) (I),
occurs in yeast and wheatgerm is an important food additive.
The availability of 3-cyanopyridine, nicotinamide and nicotinic acid
make possible their use as synthetic intermediates.
Most derivatives are prepared by manipulation of pyridine and its
simple homologues in a manner similar to chemistry of the benzenoid
chemistry. However the simple pyridine compounds are prepared by the
cyclisation of aliphatic raw material.
SYNTHETIC ASPECTS
Preparation of 3-cyanopyridines have been cited in literature 233-237 with
different methods. The well known method is:
126
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1. Samour and co-workers238 have prepared substituted cyanopyridines by
the condensation of chalcones with malononitrile in presence of
ammonium acetate.
MECHANISM
The mechanism for the condensation of chalcones with malononitrile is
shown as under.
This reaction proceeds through conjugated addition of active
methylene compounds to the α, β unsaturated system. The α, β-unsaturated
compound is known as acceptors and active methylene compound is known
as addender.
127
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THERAPEUTIC EVALUATION










S. S. Verma et al.248 have synthesised 2-amino-3-cyano-2,6-disubstituted
pyridines and studied their biological activities. The insecticidal activity of
cyanopyridines has been investigated by Y. Sosaki249, I. Teu and
co-workers250 have shown cyanopyridines as agrochemical fungicides. M.
Hussans and co-workers251 have prepared 3-cyanopyridines and reported their
pharmacological activity. S. Guru evaluated252 cyanopyridine derivatives (III)
have been documented for their multiple biological activities.
F. Manna  and co-workers253 have reported the antiinflammatory activity
of 3-cyanopyridines. Some new 3-cyanopyridine derivatives have been found
128
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to show anticancer and anti HIV activity.254 A. R. Parikh et al.255-256 have
prepared some new cyanopyridines and studied .their antimicrobial activity.
U. D. Pyachenko and co-workers257 have synthesised some
cyanopyridine derivatives (IV) which are useful in the treatment of retroviral
diseases. Cyanopyridine derivatives (V) showing significant biological
activity are described258
H. H. Parekh et al.259 have prepared new cyanopyridines and all
products have been evaluated for their in vitro growth inhibitory activity against
different microbes. T. B. Lowinger et al.260 have prepared some new
cyanopyridines and postulated them as vitro and cellular activities.
Moreover, H. Hiroki et al.261 synthesised 2-acylamino-3,5-
dicyanopyridine derivatives useful as calcium channel opening drugs.
Antimicrobial activity of cyanopyridine derivatives have reported by M. M.
Komal262, E. B. Villhauer et al.263 have prepared novel cyanopyridines which
has been found to be bioavailable dipeptidyl peptidase inhibitors.
The synthesis of cyanopyridines is of current interest owing to their
enormous occurence in biologically active derivatives. Hence,
considerable attention has been focused on the study of efficient and
pharmaceutically important cyanopyridines bearing dibenz [b,f]-azepines
nucleus, which is described as under.
129
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds

















Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(6"-
ARYL)2"-AMINO-3"-CYANO PYRIDINE-4"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Pyridine nucleus plays in important role in medicine agriculture and
industrial chemistry. To further assess the potential  of such a classes of
compounds, cyano pyridine derivative of 5-{4'-[(6"-Aryl) - 2"-amino-3"-
cyano pyridine-4"-yl] phenyl carbamido}-dibenz [b,f] azepines of type (IX)
have been  synthesised  by the condensation of chalcones of 5-{4'-[(3"-aryl)-
2"-propene -1"one]- phenyl carbamido}- dibenz [b,f] azepines with
malononitrile in presenese of ammonium acetate.
The constitution of the  products  have been characterised by elemental
analyses IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I,section : I, Page No. 32-34




























































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :DMSO: Instrument : DPX-200 Spectrometer
(200MHz)
NMR SPECTRAL STUDY OF 5-{4'-[6"-(4'"-METHOXY PHENYL)]


































































































































































































































































































































































































































































































































































































































































































40% NaOH, 24 hrs Stirring
CH2(CN)2
CH3COONH4








Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(6"ARYL)-2"-AMINO-3"-CYANO PYRIDINE-
4"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f] AZEPINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I section : I, Page No. 31
(C) Synthesis of 5-{4'-[6"-(4"'-methoxy phenyl)-2"-amino 3"-4"-
cyano pyrimidine -4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]-
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g ,0.01M) and malononitrile
(0.66g, 0.01M) and ammonium acetate (0.77g, 0.001M) was refluxed 10 hrs
at 120.oC  in methanol  solvent the reaction mixture was poured into crushed
ice, filtered and dried the product was isolated, crystallised from dioxane:
yield 66.75%, M.P. 85OC (Found:C:76.16; H: 4.61; N:12.98; C34H25N5O2
Required: C:76.26; H:4.67; N: 13.08 %)
Simillary other compounds  were synthesised and their  physical data
are recorded in Table No.17
(D) Antimicrobial activity of 5-{4'-[(6"-aryl)-2"amino-3" cyano
pyridine- 4"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I Page No. 32-34
The zone of inhibition of the test solutions  are recorded in Table No. 18
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Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SECTION : II
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(4"-
ARYL)3"-CYANO-2"-METHOXY PYRIDINE-6"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Pyridine nucleus plays in important role in medicine agriculture and
industrial chemistry. To further assess the potential of such a class of
compounds, cyano pyridine derivative of 5-{4'-[(4"-Aryl) - 3"-cyano -2"-
methoxy pyridine 6"-yl] phenyl carbamido}- dibenz [b,f] azepines by the
condensation of 5-{4'-[(3"-aryl)-2"-propene-1"one]- phenyl carbamido}-
dibenz [b,f] azepines type (I) with malononitrile and sodium methoxide.
The constitution of the  products  have been characterised by elemental
analysis IR,1H  NMR,Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section :I, Page No. 32-34

























IR SPECTRAL STUDY OF 5-{4'-[4"-(4"-METHOXY PHENYL)-3"-

















































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :CDCl3: Instrument : BRUKER Spectrometer
(300MHz)
NMR SPECTRAL STUDY OF 5-{4'-[4"-(4"'-METHOXY PHENYL) -


































































































































































































































































































































































































































































































































































































































































































































40% NaOH, 24 hrs Stirring
CH2(CN)2
CH3ONa









Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(4"ARYL)-3"-CYANO-2"-METHOXY
PYRIDINE 6"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f]
AZEPINES
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I, section : I, Page No : 31
(C) Synthesis of 5-{4'-[4"-(4"'-methoxy phenyl)-3"-cyano- 3"-2"-
methoxy pyridine -6"-yl]-phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepine. (4.72.g, 0.01M) and malononitrile
(0.66g, 0.01M) and sodium methoxide as solvent was refuxed 10 hrs. at
100.oC. The reaction mixcture was poured into crushed ice, filtered and dried
the product was  isolated, crystallised from dioxane: yield :78.80 % M.P.
70OC (Found:C:76.32; H: 4.70; N:10.11; C35H26N4O3
required: C:76.36; H:4.72; N:10.18 %)
Simillary other Compund were prepared and their physical data are
recorded in Table No. 19
(D) Antimicrobial activity of 5-{4'-[(4"-aryl)-3"-cyano-2"-methoxy
pyridine-6"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 20
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SECTION : III
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(4"-
ARYL)-3"-CYANO-2"-ETHOXY PYRIDINE-6"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Pyridine nucleus plays in important role in medicine agriculture and
industrial chemistry. To further assess the potential of such a class of
compounds, cyano pyridines derivative of 5-{4'-[(4"-Aryl)-3" cyano-2"-
ethoxy pyridine 6"-yl] phenyl carbamido}-dibenz [b,f] azepines by the
condensation of 5-{4'-[(3"-aryl)-2"-propene -1"one]- phenyl carbamido}-
dibenz [b,f] azepines type (I) with malononitrile and sodium ethoxide.
The constitution of the  products  have been characterised by elemental
analysis IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part :I, Section I, Page No.32-34


























IR SPECTRAL STUDY OF 5-{4'-[4"-(4"-METHOXY PHENYL) -3"-























































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :CDCl3: Instrument : BRUKER Spectrometer
(300MHz)













































































































































































































































































































































































































































   




















    
    








    
    















































































































































































































40% NaOH, 24 hrs Stirring
CH2(CN)2
C2H5ONa
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EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(4"-ARYL)-3"-CYANO-2"-ETHOXY
PYRIDINE 6"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f]
AZEPINES
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I section : I,  Page No : 31
(C) Synthesis of 5-{4'-[4"-(4"'-methoxy phenyl)-3"-cyano-2"-ethoxy
pyridine -4"-yl]-phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and malononitrile
(0.66g, 0.01M) and sodium ethoxide as solvent was poured into crushed ice,
filtered and dried the product was  isolated, crystallised from dioxane:
yield :81.10 % M.P. 82OC (Found:C:76.52; H: 4.80; N:9.80; C36H28N4O3
required: C:76.59;  H:4.96;  N:9.92 %)
Simillary other pyridine were synthesised and their physical data are
recorded in Table No. 21
(D) Antimicrobial activity of 5-{4'-[(4"-aryl)-3"cyano-2"-ethoxy
pyridine-6"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 22
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SECTION : IV
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF  5-{4'-[(4"-
ARYL)-3"-CYANO-2"-HYDROXY PYRIDINE-6"-YL]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Pyridine nucleus plays in important role in medicine agriculture and
industrial chemistry. To further assess the potential of such a class of
compounds, cyano pyridine derivative of 5-{4'-[(4"-Aryl)-3"-cyano-2"-
hydroxy pyridine 6"-yl] phenyl carbamido}- dibenz [b,f] azepines by the
condensation of 5-{4'-[(3"-aryl)-2"-propene -1"one]- phenyl carbamido}-
dibenz [b,f] azepines type (I) with ethyl cyano acetate in presence of
ammonium acetate.
The constitution of the  synthesised  products  have been characterised
by elemental analysis IR,1H  NMR, Mass spectral study. The products were
screened for antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section I, Page No 32-34
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IR SPECTRAL STUDY OF 5-{4'-[4"-(4"'-METHOXY PHENYL) -3"-





















































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :DMSO: Instrument : BRUKER Spectrometer
(300MHz)
NMR SPECTRAL STUDY OF 5-{4'-[4"-(4'"-METHOXY PHENYL) -









































































































































































































































































































































































































































































































































































































































































40% NaOH, 24 hrs Stirring
Type (XII)                            R=Aryl










Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(4"-ARYL)-3"-CYANO-2"-HYDROXY
PYRIDINE-6"-YL]-PHENYL CARBAMIDO}-DIBENZ [b,f] AZEPINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I section : I , Page No : 31
(C) Synthesis of 5-{4'-[4"-(4"'-methoxy phenyl)-3"-cyano-2"-hydroxy
pyridine -6"-yl]-phenyl carbamido}-dibenz [b,f] azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and ethyl cyano ac-
etate (1.13ml, 0.01M) was refluxed for 10 hrs. at 110oC in presence of ammo-
nium acetate in methanol poured into crushed ice, filtered and washed. The
product was crystallised from ethanol yiled: 80.82 % M.P. 85OC
(Found:C:76.09; H: 4.32; N:10.08; C34H24N4O3 Required: C:76.20; H:4.34;
N:10.44 %)
Simillary other compunds were prepared and their physical data are
recorded in Table No.23
(D) Antimicrobial activity of 5-{4'-[(4"-aryl)-3"cyano-2" hydroxy
pyridine-6"-yl] phenyl carbamido}-dibenz [b,f] azepines.
The antimicrobial testing was carried out as described in part : I,
section: I, Page No.32-34
The zone of inhibition of the test solution are recorded in Table No. 24
168


























































































































































































































































































































































































































































































































































































































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
STUDIES ON CYANO PARANS.
INTRODUCTION
Pyran derivatives are associated with wide range of applications in
various fields like pharmaceutical, dyes, insecticides and sweet smelling
substances. Pyran ring system also occurs in nature abundantly such as in
large number of natural coloured compounds, in vitamine E, in cloves, in
fich poisons, in certain alkaloids and other substances.
Pyran are six member doubly unsaturated compounds containing one
oxygen atom in the ring. The double bonds may be conjugated known as α-
or 1,2-pyran or it may be isolated known as γ -or 1,4-pyran.
SYNTHETIC ASPECT
Various methods for the preparation of pyran derivatives have been
cited in the literature264-273
1. Reaction between α, β− unsaturated carbonyl system with malononitrile
led to correspnding 2-amino-3-cyano-4H-pyran274
2. A. Z. Elssar  et al1275 prepared 3-cyano-pyran derivatives by the reac
tion of α-cyano chalcone derivatives with C2H5COCH2COOCH3 in ba
sic medium.
172
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
3. Abdel-Ghany H. et al.276 have been synthesized cyano derivatives by the
reaction of 2-coumariylidene malononitrile with active methylene
containing compounds.
4. β-Siloxy acrylonitrile were reacted with chalcones to furnish the
respective cyano-4H-pyran derivatives277
5. M. G. Assay et al.278 have synthesized some cyanopyran derivatives by
the reaction of cyclohexenone with cinnamon nitriles.
6. R. De Lera Angel  and co-workers279 synthesized pyran derivatives by
thermal electrolytic ring closure of divinylallenals.
7. In recent, A. M. Hussein and et al.280 prepared some novel derivatives
of cyanopyran.
173
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REACTION MECHANISM
The reaction mechanism for the formation of pyran derivatives proceeds
through Micheal addition of active methylene group of malononitrile to the
β-carbon atom of chalcone described as under.
THERAPEUTIC IMPORTANCE
Polysubstituted pyran derivatives arc biologically interesting class of














M. A. AI-Haiza and co-workers295 prepared some cyanopyran
derivatives (I) and tested their antibacterial and antifungal activities. A. V. Samet
296 et al. aynthesized 2-amino-5-azolyl-3-cyano-4H-pyrans (II) and evaluated
for biological activity. A. Z. Elassar et al 297 reported that cyanopyran
exhibited in vitro antifungal and antibacterial activities.
Moreover,  R. M. Shaker.298 have prepared some coumarin ring
containing 2-amino-3-cyanopyran (III) derivatives and studied their
antimicrobial activity. Y. D. Kulkarni and co-workers299 synthesized some pyran
derivatives as CNS active agents. A. A. Hassainien et al300 prepared 2-
amino-3-cyano-7,7-dimethyl-4-substitutedphenyl-5-oxo-4,5,6,8-tetrahydro-
pyran and tested for their biological activities.
175
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Further more, A. Krauze,  et al301 synthesized 5-(4-pyridyl) derivatives of 2-
amino-4H-pyran (IV) for antimicrobial activity S. Fowzia Al-Saleh302 and
coworkers synthesized some new cyanopyran derivatives and reported them
as antimicrobial agents. Some pyran derivatives have been pantented for their
use as gastric acid secretion inhibitors303 inhibitors of cell proliferation304
antihypertensive305 antitumor306 antagonists307-308 and antiviral agents309
H.S. Joshi et al310 and co-workers recently have synthesized some new
cyano pyran (V) derivatives as anticancer and antimicrobial agents.
Thus with an effort to capitalize the biological potential of the
heterocyclic system and to synthesize interesting compounds having better
biological potential, the titled compounds have been investigated which have
been described as under.
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-[(2"-
AMINO)-(4"-ARYL)-4"-(H)-PYRAN-3-CARBONITRILE-6"-YL]
PHENYL  CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Cyanopyran derivatives have been reported to have various
pharmalogical activities like antibacterial, antisecreatery, antiviral, antifungal
etc. In order to develope better medicinally important compounds. It was
considered of interest to synthesised some cyanopyran derivatives shown as
under. cyanopyran derivatives of 5-{4'-[(2"-amino)-(4"aryl)-4"(H) pyran 3-
carbonotrile 6"-yl] phenyl carbamido}-dibenz [b,f] azepines of type (XIII)
have been synthesised by the reaction of the chalcones of 5-{4'-[(3"-aryl)-2"-
Propene -1"-one]-phenyl carbamido}-dibenz [b,f] azepines with malononitril
in pyridine.
The constitution of the  products  have been characterised by elemental
analysis IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section I, Page No : 32-34








































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :DMSO: Instrument : BRUKER Spectrometer
(300MHz)
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40% NaOH, 24 hrs Stirring
CH2(CN)2
in Pyridine













(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f]-azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I, section : I Page  No. 31
(C) Synthesis of 5-{4'-[(2"- Amino)-4"-(4"'-methoxy phenyl)-4"-(H)-
pyran-3-carbonitrile-6"-yl] phenyl carbamido}-dibenz [b,f]
azepines.
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and malononitrile
(0.66g,0.01M) in pyridine was refluxed for 12 hrs. at120oC in methanol (10
ml) the reaction mixture was poured into crushed ice, filtered and washed
then crystalized from ethanol yield :80.82 % M.P. 108OC (Found:C:75.73; H:
4.63; N:10.35; C34H26N4O3 Required: C:75.83; H:4.83; N: 10.40 %)
Simillary other pyran derivatives were prepared and their physical data
are recorded in Table No. : 25
(D) Antimicrobial activity of 5-{4'-[(2"-amino)-(4"-aryl)-4"-(H)-
pyran3-carbonitrile 6"-yl]-phenyl carbamido}-dibenz [b,f] azepines.
The Antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 26
184
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STUDIES ON QUINOXALINES.
INTRODUCTION
The quinoxaline or benzopyrazine (I) are the product formed by
spontaneous condensation of  o-phenylene diamines with 1,2-dicarbonyl
compounds.
This reaction was discovered by Korner311 and by Hinsberg312 independ-
ently. Since qnuinoxalino are also obtained when α−β−dihalo ketones
condensed with o-phenyline diamine. The structure of these cyclic base are
obvious from the mode of formatiora and analytical data. The ring structure
was further confirmed by Gabriel and Sonn, who demonstrated experimen-
tally the relationship between the quinoxaline and the pyrazines by
oxidizing quinoxaline to pyrazine-2,3-dicarboxylic acid.
SYNTHETIC ASPECT
Different methods are available in literature313-316 for the preparation of
quinoxalines. The popular methods are :
(1) M. L. Keshtov and co-worker317 have been prepared dimer type
quinoxaline derivatives (II)
188
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(2) Quinoxaline derivative318(III) are prepared by reaction of Nitrobenzene
with  NH2OR in presence of Cu catalysts and reaction of nitroanilines
and presence of hydrogenation catalyst.
(3) S. K. Kanungo et al.319 have prepared 1,3-Dimethylpyrrolo quinoxaline-
2-ones from chloroacetic acid and o-pheniline diamine.
BIOLOGICAL  IMPORTANCE
Quinoxaline derivatives have been found to possess wide range of
therapeutic activities.













1-(Aminoalkyl)-3-quinoxaline-2-one derivatives were prepared as
neuroprotective agents by K. Ehrenberger and F. Dominik333 . A new series of
sulfonamido quinoxaline were synthesised and assessed for various
biological activity334, antibiotics action of some novel quinoxaline derivative
were studied by T. V. Alfreson335 and co-workers.
V.-Gabriella and co-workers336 have formulated some new quinoxaline.
derivative (IV) as in vitro anticancer activity.
Recently, serveral co-workers have been prepared quinoxaline
derivatives by different methods which possess AMPA receptor antaqonist
and antihistaminic337-339,antagonist340-341, human dopamine D4 receptor342,
antibacteriala343, antimicrobial344-346, anticancer347,and antitumor348, activities.
More recently, B. Konig et al.349 have synthesised quinoxaline derivatives
which has activation of PPARa and PPAR gamma reduces triacyglycerol G.
Sarodrick, T. G. Linker et al.350 have prepared quinoxaline. derivatives having
190
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bactericidal, algecide, fungicide activity for agriculture use. Quinoxaline
derivative used PDGE receptor and LCK tyrosine kinase inhibitors
In order to achieve better therapeutic agent, the preparation of quinoxaline
derivatives has been taken as under.
SECTION : I SYNTHESIS AND ANTIMICROBIAL ACTIVITY
OF 2"-ARYL-[(3"-METHYL PHENYL CARBAMIDO)]
-5-DIBENZ [b,f] AZEPINES QUINOXALINES.
191
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 2"-ARYL[(3"-
METHYL PHENYL CARBAMIDO)]-5-DIBENZ [b,f,] AZEPINES
QUINOXALINES.
Quinoxalines have been found to possess wide range of therapeutic
activity and  industrial importance these significant biological properties
have aroused considerable interest to design compounds in which dibenz
[b,f] azepines nucleus is incorporated with a view to getting compounds with
better drug potential. The quinoxalines of 2"-aryl [(3"-methyl phenyl
carbamido]-5-dibenz [b,f] azepines quinoxalines of type (XIV) have been
synthesised by condensation of chalcones of 5-{4'-[(3"-(4"-methyl phenyl))-
2",3"-dibromo-1"-one]-phenyl carbamido}-dibenz [b,f] azepines, with
o-phenylline diamine.
The constitution of the  products have been characterised by elemental
analysis IR,1H  NMR, Mass spectral study. The products were screened for
antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section I. Page No. 32-34























IR SPECTRAL STUDY OF 2"-[(4"'-METHOXY PHENYL)-(3"-
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NMR SPECTRAL STUDY OF 2"-[(4"'-METHOXY PHENYL)-(3"-
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EXPERIMENTAL
SYNTHESIS 2"-(4"'-ARYL) [(3"-METHYL PHENYL CARBAMIDO)]
-5-DIBENZ [b,f] AZEPINE QUINOXALINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f] azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I, section : I, Page  No : 31
(C) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2",3"-dibromo-1"-
One]-phenyl carbamido}-dibenz [b,f] azepines.
A chalcone type (I) (0.01M) was dissolved in acetic and (30 ml) a
bromine in acetic acid (1 ml) 10 % was  slowely added to it. the reaction
mixture was stirred for 2 hrs. It was poured into water and crystallised from
ethyl alcohol blackish yellow needles.
(D) Synthesis of 2"-(4"'-Methoxy phenyl) [(3"-methyl phenyl
carbamido)]-5-dibenz [b,f] azepine quinoxalines.
A mixture of 5-{4'-[3"-(4"-methoxy phenyl)-2",3"-dibromo-1"-one]-
phenyl carbamido}-dibenz [b,f]-azepine (6.30g, 0.01M) and O-pheneline
diamine (1.08g, 0.01M) and taken in methanol (25 ml). A few  drops of con.
H2SO4  was added and then reaction mixture was heated at 70-75
oC for 30
min on waterbath. It was then diluted with water and crude mass was ex-
tracted with solvent ether to remove insoluble O-phenelinediamine. Ether was
remove and separate solid was crystalised from ethanol, yiled :75.80 % M.P.
80OC 79.14 (Found:C:79.14; H: 4.99; N:9.95; C37H28N4O2 required: C:79.19;
H:5.96;  N:10.00 %)
199
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Simillary other componds were prepared and their physical data are
recorded in Table No. 27
(E) Antimicrobial activity of (2"-aryl)-[(3"-methyl phenyl carbamido)-
5-dibenz [b,f] azepine quinoxalines..
The antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 28
200
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STUDIES ON CYCLOHEXENONES
INTRODUCTION
Cyclohexenones are derivatives of cyclohexane with carbonyl grooup
at position -1 and double bond at position -2 (I). There are different types of
cyclohexenone derivatives but the greatest difference in structure and
properties is exerted by the groups attached to carbon atom.
SYNTHETIC ASPECT
Different methods for the preparation of cyclohexenone derivatives have
been described in literature351-364
(I) A review of the earlier literature by D.Gerald et al.365 described
representative synthetic procedure of cyclohexenone derivative (I).
(II) Page Philip C. and co-workers366 have been prepared substituted
cyclohexenone derivatives (II)
204
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(III)H.A. Eman et al.367 have been prepared cyclohexenone derivatives
(III) from chalcone.
(IV) Shklyaev et al368 have been synthesized 1-substituted (R,S) -8- methox5-
methylphenyl)-3,3,9-trimethyl-2-azaspiro [4,5] deca-1,7- d i e n - 6 - o n e s
(IV).
205
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THERAPEUTIC IMPORTANCE
Cyclohexenone have various medicinal applications such as anthelmintic,
hypoglycemic, nematocidal, antibacterial, antifungal, antiviral, analgesic etc.
Antiarhythmic activity369 of some cyclohexenone derivatives have been
investigated. Cyclohexenone possess cardiovascular, osteoporosis, menpausal
symptoms, estrogen dependent, cancer activities, which was reported by
P.Jacobsen  et al.370,N.D. Eddington et al 371 synthesize ethyl 4-[(substituted
phenyl) amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylates (I) and screened
their anticonvulsant activity. C. Edward  et al.372 also prepared 2,3-dihydro-5-
(3-oxc-2-cyclohexen-1-yl)-2-benzofurancarboxylic acids (II) and their salts
which are used in the treatment of brain injury.
Cyclohexenone and its derivatives have been prepared and reported as
broad. spectrum of physiological properties viz., antibiotics373-374 bactericidal375
herbicidal376 antimicrobial377, anticonvulsant378 etc. L.M.Alekseeva  and
co-workers379 have synthesized cyclohexenone derivatives which are as useful
as neurotropic activity. S.Toshiyuki et al.380 have prepared some novel
cyclohexenone and screened for allergy inhibitor, antithrombotic platelet
aggregation inhibitors and fibrinogen antagonist activity.
206
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Recently, antimicrobial activity have been studied by M.A.Salama and
Atshikh381 Cyclohexenone possess neutropeptide γ-receptor antagonist
activity which was reported by F. Takehiro and co-workers382, B. B. Howard383
have demonstrated cyclohexenone as GABA α5 receptor ligands for enhanc-
ing coagulating properties. Cyclohexenone possess inhibitory activity against
the growth of lettuce seeding found by Y. Kimura and co- workers384
The presence of pesticidal activity among cyclohexenone derivatives is
well documented. The compound 2-{(E,Z)-1-[(2R,S)-2-(4-chlorophenoxy)
propoxy imino] butyl}-3-hydroxy-5-thian-3-yl) cyclohex-2-en)-one (III) has
been marketed under the name of 'Profoxydim' as an herbicides.
These valid observation led us to synthesize new cyclohexenone
derivatives bearing cinnoline nucleus in search of agent having better
therapeutic potential which have been described as under.
SECTION - I SYNTHESIS AND ANTIMICROBIAL ACTIVITY
OF ETHYL -[(6"-ARYL) 4"-PHENYL CARBAMIDO]
-5-DIBENZ [b,f] AZEPINES -2"-OXO CYCLOHEX-
3"-ENE-1"-CARBOXALATE
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF ETHYL -[(6"-
ARYL) 4"-PHENYL CARBAMIDO]-5-DIBENZ [b,f] AZEPINES -2"-
OXO CYCLOHEX-3"-ENE-1"-CARBOXALATE
Cylohexenone derivatives have considerable attention in view of their
potential pharmacological properties such as antimicrobial, anticonvulsant,
anticancer etc. Led by these consideration the preparation of cyclohexenone
derivaties of Type (XV) has been undertaken. The synthesis was carried out
by the condensation of 5-{4'-[(3"-Aryl)-2"-propene-1"-one]-phenyl
carbamido}-dibenz [b,f] azepines, with ethyl acetoacetate .
The constitution of the  products have been characterised by elemental
analysis IR,1H  NMR, and Mass spectral study. The products were screened
for antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section I ,Page No. : 32-34


































































































































IR SPECTRAL STUDY OF ETHYL- [6"-(4'"-METHOXY PHENYL)
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Intrenal standard : TMS; solvent :DMSO: Instrument : BRUKER Spectrometer
(300MHz)
NMR SPECTRAL STUDY OF ETHYL-[6"-(4'"-METHOXY
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EXPERIMENTAL
SYNTHESIS OF ETHYL -[(6"ARYL)-4''-PHENYL CARBAMIDO]-
5-DIBENZ [b,f] AZEPINES-2"-OXOCYCLOHEX-3"-ENE-1"-
CARBOXALATE.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f]-azepine
For synthesis see part-I, section : I, Page No: 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I, section : I, Page  No : 31
(C) Synthesis of ethyl[6"-(4'"-methoxy phenyl)-4"-phenyl carbamido]-
5-dibenz [b,f] azepines-2"-oxo-cyclohex-3"-ene-1"-carbaxalate
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and dissolve in 30ml
dioxane and add sodium ethoxide (0.15ml) and ethyl acetoacetate (2.60g,
0.02M) and reaction was refluxed on oil bath for 12 hrs. The reaction mix-
ture was cooled and poured over crushed ice, The product was isolated and
crystalized from toluene yield :79.10 %, M.P. 290OC (Found:C:75.88; H:
5.41; N:4.71; C37H32N2O5 Required: C:75.89; H:5.45; N: 4.79 %)
Simillary other compounds were prepared and their physical data are
recoaded in Table No. 29
(D) Antimicrobial activity of ethyl-[(6"-aryl))-4"-phenyl carbamido]
5-dibenz [b,f] azepines-2"-oxo cyclohex-3"-ene-1"-carboxalate
The Antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 30
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STUDIES ON  BARBITONES.
INTRODUCTION
The emerging role of barbitones in pharmaceutical chemistry as well as in
biochemistry stimulated tremendous interest in the synthesis of barbitones of
therapeutic interest. Most important is the effect of barbiturates on the central
nervous system. Barbituric acid derivatives constitute an important class of
compounds possessing diverse type of biological properties including
hypnotic, sedative, anticonvulsant, cardiovascular etc.
Derivatives of barbituric acid are perhaps the most widely used pyrimidines
in medicine. Veronal (I) and Luminol (II) possess hypnotic activities, while
pentothiol (III) is used as an anaesthetic.
SYNTHETIC ASPECT
Different methods for the synthesis of barbitones have been described in
literature385-389
1. M. R. Mahmoud et al.390 have synthesized barbituric acid derivatives from
chalcones.
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
2. Cao-Yun et al391 have prepared barbituric acid derivatives by the reaction
of different aldehydes with barbituric acid in basic media.
3. R. K. Roy et al392 have synthesised  barbituric acid derivatives by the
reaction of urea derivatives with malonic acid.
THERAPEUTIC EVALUATION
At present great interest is being taken in barbituric acid derivative  be-
cause of its biological activity and their relation with nucleic acids, viz uracil,
thymine and cytosine.
Some barbiturates showing cardiovascular393-394 antiinflammatory395 and
pesticida396 activities have been reported. D. Peters et al397 have synthesised
seme uracil derivatives and screened for antiviral activity. R. Raymond et al398
synthesised some barbiturates (IV) which showed anticancer activity.
220
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Several co-workers have synthesised barbitone derivatives and reported
their antagonist399 antitumor400 anticonvulsant401 and metalloproteinas
inhibitor402ctivities. Abdel-Hamide and co-workers403 have prepared barbituric
acid derivatives (V) having anticonvulsant activity. A. N. Shivanyuk at al404
have demonstrated barbitone derivatives as porphyrin melamine calixarene
receptor. Wolf-Gang et al405have reported 5-(3-benzylthiazoIidine-2-yIidene)-
1,3-dimethyl hexahydro pyrimidine-2,4,6-trione having agricultural activity Some
barbituric acid derivatives used as herbicides and insecticides have beei dem-
onstrated.406
M.T. Omar 407 has synthesised barbitone derivativse showing antimicrobia
activity. Sakai et al408 have synthesised some new barbitones which were
assessed for bone and cartilage disease, F. Grams and G. Zimmermantv409
have prepared barbitones as metalloprotease inhibitors. Some barbitone de-
rivatives have been studied for their antitumor activity410
Moreover, isotylidene barbiturates (VI) showing antibacterial activity have
been synthesised411 D. Geppert and co-workers412 have prepared new pyrimidine-
2,4,6-triones (VII) as metalloproteinase inhibitors.
221
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Keeping in view the important biological activities possessed by
barbituric acid derivatives, we have tried to synthesise some new barbitones
having better biological activities.
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SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-[(3"-
ARYL)-2"-PROPENE-1"-BARBITURIC ACID]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
Barbituric and derivatives are claimed to have a wide spectrum of
biological activities. Dibenz [b,f] azepines moity possess diversified boilgical
properties considering all the above facts it was thought that if barbituric
acid group, the could be introduced to dibenz [b,f] azepines moiety, the
resulting compounds might have some significant biological properties. For
this purpose some new barbituric acid derivatives of 5-{4'-[(3"-Aaryl)-2"-
propene-1"-barbituric acid] - phenyl carbamido}-dibenz [b,f] azepines, of
type (XVI) have been synthesised by the condensation of 5-{4'-[(3"-aryl)-2"-
propene-1"-one]- phenyl carbamido}- dibenz [b,f] azepines with barbituric
acid.
The constitution of the  products have been characterised by elemental
analysis IR,1H  NMR, and Mass spectral study. The products were screened
for antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section I, Page No. 32-34
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Intrenal standard : TMS; solvent :DMSO: Instrument : BRUKER Spectrometer
(300MHz)
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EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(3"-ARYL)-2"-PROPENE-1"-BARBITURIC
ACID]-PHENYL CARBAMIDO}-DIBENZ [b,f] AZEPINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f]-azepine
For synthesis see part-I, section : I, Page No. 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I, section : I, Page  No. 31
(C) Synthesis of 5-{4'-[3"-(4'"-methoxy phenyl)-2"-propene-1"-
barbituric acid]-phenyl carbamido}-dibenz [b,f] azepines
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and barbituric acid
(1.28g, 0.01M) was refluxed 12 hrs. in presence of  gla. CH3COOH in
methanol. The reaction mixture was poured in crushed ice, filtered washed
and dried, crystallized from ethanol, yield :71.41 %, M.P. 120OC
(Found:C:72.08; H: 4.42; N:9.59; C35H26N4O5  Required: C:72.80; H:4.44; N:
9.62 %)
Simillary other compounds were synthesis and their physical data are
recorded in Table No. : 31
(D) Antimicrobial activity of 5-{4'-[(3"-aryl)-2"-propane 1"-barbituric
acid]-phenyl carbamido-dibenz [b,f] azepines
The Antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 32
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STUDIES ON THIOSEMICARBOXIMIDES.
INTRODUCTION
Thiosemicarbazone derivatives are of special importance because of their
versatile biological and pharmacological activities. Thiosemicarbazone
derivatives have found applications in drug development for the treatment of
central nervous system disorders, of bacterial infections, as well as analgesic
and antiallergic agent. They are potent intermediates for the synthesis of
pharmaceutical and bioactive materials.
The clinically active drug methisazone and related compounds have shown
activity against DNA viruses, principally the Orthopoxviruses, both in vitro
and in vivo.
SYNTHETIC ASPECT
Nowadays reaction between thiosemicarbazide with ketones or aldehydes
have attracted a great attention, because of their interesting nature of resulting
compounds for their applications and biological activities.
Different methods are used for the synthesis of thiosemicarbazones which
is described in literature413-416
1. A. B. Tomchin417 has synthesised thiosemicarbazones by the recyclisation
of 2-amino-5-{2-aminoaroyl)-l,3,4-thiadiazoles.
234
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2. Y. Perumal and co-workers418 have prepared thiosemicarbazones by the
condensation of 6-chlorobenzothiazolyI-2-thiosemicarbazide with aldehydes
or ketones.
THERAPEUTIC EVALUATION
Thiosemicarbazones exhibit a wide variety of  biological activities which










Antimicrobial  activity of thiosemicarbazone  derivatives  have  been
reported429-430,T. Siatra et al.431 have synthesised some new thiosemicarbazones
235
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from 3-acetyl indole and reported its effect on DNA synthesis and cell
proliferation. 5-chloro salicyaldehydic thiosemicarbazone derivatives have been
documented by Z. Quianawin et al.432
N-substituted thiosemicarbazones showing antitumor activity have been
reported433,D. Wang et al.434 patented thiosemicarbazones useful as sodium
channel blockers. KIzabella 435 has prepared thiosemicarbazones (I) from 1,3-
cyclic diamino and reported as anticancer agent. O.V. Fedorova et al.436
synthesised some thiosemicarbazones (II) having potent in vitro tuberculostatic
activity.
Some 3-aminopyrimidine 2-carboxaldehyde thiosemicarbazone
derivatives are reported as novel prodrug forms of ribonucleotide reductase
inhibitors 3-AP and 3-AMP by Li Jun et al.437
Some new thiosemicarbazone derivatives have been studied for their
anticancer activity438 D. Sharma et al. 439  have synthesised thiophene 2-
carboxaldehyde thiosemicarbazones and evaluated their antimicrobial and
antiviral. S.P.R. Rodiriguez and co-workers440  have synthesised 4-substituted
thiosemicarbazones and reported its antiproliferartive activity.
Thiosemicarbazone derivatives as potent antiviral agents nave been investi-
gated.441
236
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Moreover, Jin Shuhui and co-workers442 thiosemicarbazones and
prepared thiosemicarbazones and reported them for antifungal activity.
Thiosemicarbazones (III) showing significant antimicrobial activity are
described.443 Nilgun K.444 have synthesised some thiosemicarbazones (IV)
bearing indol nucleus and evaluated their cytotoxicity.
Due to the physiological and biological activities of thiosemicarbazones,
it was contemplated to synthesise some new thiosemicarbazones with a hope
that these compounds may have better pharmacological activities.
SECTION - I : SYNTHESIS AND ANTIMICROBIAL ACTIVITY
OF 5-{4'-[(3"-ARYL)-2"-PROPENE-1"-THIOS
EMICARBOXIMIDES]-PHENYL
CARBAMIDO} -DIBENZ [b,f] AZEPINES.
237
Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
SECTION : I
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5-{4'-[(3"-
ARYL)-2"-PROPENE-1"-THIOSEMICARBOXIMIDES]-PHENYL
CARBAMIDO}-DIBENZ [b,f] AZEPINES.
With a view to getting better antimicrobial activity and considering the
association of various biological activites with thiosemicarbazones, we have
synthesised 5-{4'-[(3"-aryl)-2"-propene-1"-thio semicarboximides-phenyl
carbamido}-dibenz [b,f] azepines, of type (XVII) by the reaction of 5-{4'-
[(3"-aryl)-2"-propene-1"-one]- phenyl carbamido}-dibenz [b,f] azepines with
thiosemicarbazide.
The constitution of the  products have been characterised by elemental
analysis IR,1H  NMR, and Mass spectral study. The products were screened
for antimicrobial activity at a concentration of 50 μg
The details have been cited in the part : I, Section I, Page No. : 32-34


























IR SPECTRAL STUDY OF 5-{4'-[3"-(4"'-METHOXY PHENYL)-2"-































































































































































Synthesis, spectral studies and therapeutic activity of  Heterocyclic compounds
Intrenal standard : TMS; solvent :DMSO: Instrument : BRUKER Spectrometer
(300MHz)





































































































































































































































































































































































































































































































































































































































































































   
   















































































































40% NaOH, 24 hrs Stirring
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EXPERIMENTAL
SYNTHESIS OF 5-{4'-[(3"-ARYL)-2"-PROPENE-1"-THIOSEMICA-
RBOXIMIDES]- PHENYL CARBAMIDO}-DIBENZ [b,f] AZEPINES.
(A) Synthesis of 5-(4'-Acetyl Phenyl carbamido)-dibenz [b,f]-azepine
For synthesis see part-I, section : I, Page No: 31
(B) Synthesis of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f] azepines.
For Synthesis see part: I, section : I, Page  No : 31
(C) Synthesis of 5-{4'-[(3"-(4'"-methoxy phenyl)-2"-propene
1"-thiosemicarboximides]-phenyl carbamido}-dibenz [b,f] azepines
A mixture of 5-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"-one]
phenyl carbamido}-dibenz [b,f]-azepine. (4.72g, 0.01M) and thiosemicarbazide
(0.91 g, 0.01M) was refluxed for 10 hrs at 100oC in presence of alcohol like
ethanol. The reaction mixture was poured in crushed ice, filtered, washed,
dride and crystallized from ethanol, yield :71.72 % M.P. 72OC (Found:C:70.45;
H: 4.95; N:12.72; C32H27N5O2S
Required: C:70.50; H:4.98; N: 12.84 %)
Simillary other compounds were prepared and their physical data are
recorded in Table No. : 33
(D) Antimicrobial activity of 5-{4'-[(3"-aryl)-2"-propane 1"-
thiosemicarboximides]-phenyl carbamido-dibenz [b,f] azepines
The Antimicrobial testing was carried out as described in part : I,
section: I, Page No. 32-34
The zone of inhibition of the test solution are recorded in Table No. 34
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